depressive disorder. depressive disorder, single episode
Conditions
Interventions
Intervention 1: Control group: placebo for 6 weeks. Intervention 2: Intervention group: Cilostazol (100 mg per day) for 6 weeks.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with coronary artery disease who underwent elective percutaneous coronary intervention or coronary-artery bypass grafting in the past three months due to angina pectoris or left ventricular dysfunction not associated with myocardial infarction. Diagnosis of major depressive disorder based on DSM-V (score between 14 and 17). Age between 40-60.
Exclusion criteria
Exclusion criteria: Patients who have taken antipsychotic drugs in the last year. Diagnosis of other psychiatric disorders. Electroconvulsive treatment in the last two months. History of thyroid disease. Inflammatory diseases, including autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, autoimmune hepatitis, migraine, Guillain-Barre syndrome, multiple sclerosis, and rheumatoid arthritis. Being pregnant or breastfeeding. History of allergy to Cilostazol. Simultaneous need for antithrombin alpha, antithrombin III, argatroban, enoxaparin, apixaban, and other drugs with severe interaction with Cilostazol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of depression. Timepoint: Weeks: 0-2-4-6. Method of measurement: By Hamilton Depression Rating Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed